ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0016

Distinct Transcriptomic and Epigenetic Profiles Mediated by Disease Activity in SLE

Yusho Ishii, James Rose, Kevin Cashman, Sakeenah Hicks, Tsuneo Deguchi, Christopher Scharer, Scott Jenks, Jeremy Boss and Iñaki Sanz, Emory University, Atlanta, GA

Meeting: ACR Convergence 2022

Keywords: B-Lymphocyte, Disease Activity, Epigenetics, Gene Expression, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 12, 2022

Title: B Cell Biology and Targets in Autoimmune and Inflammatory Disease Poster

Session Type: Poster Session A

Session Time: 1:00PM-3:00PM

Background/Purpose: SLE is an autoimmune disease heterogenous for symptoms, disease severity and therapeutic response. This heterogeneity makes stratifying patients difficult. B cells from SLE patients differ transcriptionally and epigenetically from healthy donors(HCD) even in mature resting naïve (rN) B cells (1). However, these studies were done on active disease patients and potentially, active and inactive patients may have still important transcriptional and epigenetic differences.
1. Scharer CD, Blalock EL, Mi T, Barwick BG, Jenks SA, Deguchi T, et al. Epigenetic programming underpins B cell dysfunction in human SLE. Nature Immunology. 2019;20(8):1071-82.

Methods: RNA-sequencing and ATAC-sequencing were performed on sorted rN and transitional 1 and 2 B cells (T1/2) from 6 HCD, 9 inactive SLE patient (SLEDAI < 5) and 8 active SLE patients (SLEDAI ≥ 5). A generalized linear model and edgeR were used to analyze differentially expressed genes (DEG) and differentially accessible region (DAR). GO biological process enrichment analysis of DEGs and DARs was performed using DAVID (2). Identification of motifs enriched in DARs was performed using the findMotifsGenome.pl function of HOMER (3). 2. Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nature Protocols. 2009;4(1):44-57. 3. Heinz S, Benner C, Spann N, Bertolino E, Lin YC, Laslo P, et al. Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. Mol Cell. 2010;38(4):576-89.

Results: B cells from both active and inactive patients differed from HCD with 251 differentially expressed genes (DEG) in active and 186 DEG in inactive patients. Similarly, both active and inactive patients were epigenetically distinct from HCD and had differentially accessible regions (DAR). DEGs clearly separated patients by disease activity, while rN from both active and inactive patients had increased expression of interferon-stimulated genes, NFkB-, MAPK- and TNFSF-related genes were enriched specifically in the active group. Differences between HCD and inactive T1/2 B cells were minimal. DAR also differed between disease states, intriguingly, DAR with binding sites for basic leucine zipper (bZip) transcription factors (TF) were enriched inactive patients, while IRF and zinc finger TF binding DAR were more common in active patients.

Conclusion: In addition to validating the SLE-specific pathways previously reported this study establishes distinct signaling regulated activation states in naïve B cells depending on disease activity, suggesting that the combination of transcriptomic and epigenetic characteristics may be a useful marker to evaluate disease activity of lupus patients. Furthermore, considering that the inactive group contained 8 patients achieving extended clinical remission, DAR remained even in the absence of any activity. Permanently reversing these epigenetic changes suggests a new therapeutic target for prolonged remission.


Disclosures: Y. Ishii, None; J. Rose, None; K. Cashman, None; S. Hicks, None; T. Deguchi, Daiichi Sankyo Company; C. Scharer, None; S. Jenks, None; J. Boss, None; I. Sanz, Bristol Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Kyverna, Visterra, Kyverna, Exagen, GlaxoSmithKline, Bristol Myers Squibb/Celgene.

To cite this abstract in AMA style:

Ishii Y, Rose J, Cashman K, Hicks S, Deguchi T, Scharer C, Jenks S, Boss J, Sanz I. Distinct Transcriptomic and Epigenetic Profiles Mediated by Disease Activity in SLE [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/distinct-transcriptomic-and-epigenetic-profiles-mediated-by-disease-activity-in-sle/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/distinct-transcriptomic-and-epigenetic-profiles-mediated-by-disease-activity-in-sle/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology